Literature DB >> 8483624

Pharmacokinetics of intravenous vancomycin in pediatric cardiopulmonary bypass surgery.

F K Hatzopoulos1, I L Stile-Calligaro, K A Rodvold, J Sullivan-Bolyai, P Del Nido, S Levitsky.   

Abstract

The purposes of this investigation were to characterize the disposition of vancomycin in children undergoing cardiopulmonary bypass (CPB) surgery and to determine whether a 15-mg/kg intravenous dose provides adequate serum concentrations during and after CPB. Six children (age range, 0.8 to 4.8 years) received intravenous vancomycin 15 mg/kg 1 to 2 hours before CPB surgery. Serial blood samples (mean, 10/patient) were collected before, during and after CPB surgery. The mean (+/- SD) vancomycin concentrations at the end of the infusion and 5 hours after the infusion were 27.3 +/- 5.7 and 5.9 +/- 3.0 mg/liter, respectively. The initiation of CPB resulted in an abrupt decrease (44.5%) in serum vancomycin concentrations; however, concentrations remained constant (range, 6.2 to 14.1 mg/liter) throughout the rest of the CPB procedure. The mean (+/- SD) values for the apparent volume of distribution, total body clearance and elimination half-life were 0.59 +/- 0.15 liter/kg, 2.94 +/- 0.93 ml/min/kg and 2.4 +/- 0.8 hours, respectively. These values were similar to those reported in the literature for children not undergoing CPB surgery. A single vancomycin dose of 15 mg/kg before pediatric CPB surgery provides serum concentrations greater than 5 mg/liter throughout the duration of the CPB procedure. To sustain these concentrations subsequent dosing of vancomycin is necessary within 6 hours after the initial vancomycin dose.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8483624     DOI: 10.1097/00006454-199304000-00008

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

Review 1.  Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis.

Authors:  Geisa Cristina da Silva Alves; Samuel Dutra da Silva; Virginia Paula Frade; Danielle Rodrigues; André de Oliveira Baldoni; Whocely Victor de Castro; Cristina Sanches
Journal:  Eur J Clin Pharmacol       Date:  2017-08-04       Impact factor: 2.953

Review 2.  Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children.

Authors:  K A Rodvold; J A Everett; R D Pryka; D M Kraus
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

3.  Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation.

Authors:  R D Amaker; J T DiPiro; J Bhatia
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children.

Authors:  Enno D Wildschut; Annewil van Saet; Pavla Pokorna; Maurice J Ahsman; John N Van den Anker; Dick Tibboel
Journal:  Pediatr Clin North Am       Date:  2012-08-29       Impact factor: 3.278

5.  Pharmacokinetic analysis of flomoxef in children undergoing cardiopulmonary bypass and modified ultrafiltration.

Authors:  Zenichi Masuda; Yuji Kurosaki; Kozo Ishino; Keita Yamauchi; Shunji Sano
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-04-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.